The study design is unique since it includes all patients who completed 3 years follow-up after the last injection of the urethral bulking agent (UBA) Macroplastique®. While it is a strong design to offer the longitudinal, not cross-sectional, outcome it doesn’t include all ROSE study patients at the time of analysis, i.e., patients with less than 3 years and drop-outs.